08/27/2026
New treatment options matter, especially for patients facing difficult diagnoses like metastatic pancreatic cancer.
Through our collaboration with Sarah Cannon Research Institute, SCRI Oncology Partners was proud to participate in the clinical research that helped contribute to the FDA approval of daraxonrasib. This milestone reflects years of collaboration, scientific discovery, and, most importantly, the patients who chose to participate in clinical trials.
Read more about this achievement below!
SCRI researchers played a role in the development of daraxonrasib,first in class targeted therapy for metastatic pancreatic cancer.